Evaluation of Clinical Efficacy and Safety of Aortal Stent-Graft Created Using 3D Printing Technology

NCT ID: NCT06969729

Last Updated: 2025-05-14

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-01
• Study Completion Date: 2027-04-30

Brief Summary

the comparison of physician-modified stent-graft created in 3D models versus custom-made devices in the treatment of complex abdominal aortic aneurysm

Detailed Description

This is randomized, multicenter, open-label, 2 -arm Study to evaluate the efficacy and safety in stent-graft application of arm A and Arm B in patients with juxtarenal or pararenal abdominal aortic aneurysm, thoracic-abdominal aneurysm type IV or type IA endoleak.

Approximately 100 eligible patients will be randomized in a 1:1 ratio into 2 arms (n=50 in each arm) Arm A treated with innovative angiosurgery intervention Arm B standard procedure Study will use an Interactive Web Response System (IWRS) for randomization. Randomization will be used to minimize bias in the assignment of subjects to treatment groups, to increase the likelihood that known and unknown subject attributes (e.g. demographic and baseline characteristics) are evenly balanced, and to enhance the validity of statistical comparisons across treatment groups.

Subjects will be randomized based on following stratification: • Site

• Aneurysm class Subject participation will include a Screening Phase, Intervention Phase, Safety follow-up and End of Study.

The screening phase will last up to 28 days before the therapeutic intervention periods starts (two hospitalizations finished with 2 angio surgery intervention) during which the subject's eligibility and baseline characteristics will be determined. The therapeutic intervention will last from randomization until second hospitalization will end with angio surgery intervention). There will be 2 follow up visits. Safety follow up will lasts 12 months.

Aorta assessment by angio CT will be performed at screening, intervention period at hospitalization no. 1 and in 30 day follow up, 12 month follow up

Conditions

Abdominal Aortic Aneurysm; Juxtarenal Aortic Aneurysm; Thoracoabdominal Aneurysm; Endoleak

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Physician-Modified Stent-Grafts Made Using 3D Aortic Template

Patients with aortic pathology undergoing implantation of physician-modified stent-grafts created using a patient-specific 3D-printed aortic template.

Group Type: EXPERIMENTAL

Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)

Intervention Type: PROCEDURE

Implantation of a physician-modified fenestrated stent-graft using a patient-specific 3D-printed aortic template, performed via an endovascular approach.

Custom-Made Fenestrated Stent-Graft

Implantation of a commercially manufactured, patient-specific custom-made fenestrated stent-graft via an endovascular approach.

Group Type: ACTIVE_COMPARATOR

Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)

Intervention Type: PROCEDURE

Implantation of a physician-modified fenestrated stent-graft using a patient-specific 3D-printed aortic template, performed via an endovascular approach.

Interventions

Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)

Implantation of a physician-modified fenestrated stent-graft using a patient-specific 3D-printed aortic template, performed via an endovascular approach.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

Female and male subjects age ≥ 18 2. Subject need to meet one of the following criteria:

• Subjects with juxtarenal or suprarenal abdominal aortic aneurysm, type IV thoracoabdominal aneurysm of diameter >5.5cm (male) and 5.2cm (female)
• Subjects with juxtarenal or suprarenal abdominal aortic aneurysm, type IV thoraco-abdominal aneurysm with aneurysm growth rate ≥ 0.5cm during 6 months
• Type IA endoleak of post-implantation of abdominal stent- graft 3. Iliac arteries morphology with aortic stent graft implantation to be restored 4. Aortic segment which is proximal to aneurysm
• Length ≥20mm
• Diameter 20mm-36mm
• Aortic suprarenal angle ≤75 degrees 5. Survival > 2 years

Exclusion Criteria

1. Female and male subjects age <18

2. Pregnancy and breast feeding

3. Allergy and hypersensitivity to matherials of which the stent- graft is composed

4. Hypersensitivity and contraindication to anti coagulation or contrast application to angio - CT which cannot be eliminated medically

5. Coagulopathy which cannot medically treated

6. Active infection which might cause stent - graft infection

7. Creatinine level > 3.0mg/dL

8. Marphan syndrome, Ehlers - Denlos syndrome

9. Unstable angina pectoris

10. Raptured aortic aneurysm caused by cardiac insufficiency

11. Unwillingness to comply with protocol procedures

12. Iliac arteries morphology adequate for stent-graft implantation

13. The diameter of the aortic flow lumen in reno-visceral aorta greater than 34mm

14. Aortic section which is proximal to celiac artery with significant number of thrombi, calcification or changed by aneurysm

15. Aorta with significant number of irregular thrombi which may lead to embolism ("shaggy aorta")

16. Diameter of proximal kidney arteries which is exercisable to stenting <4.5mm

17. Devision of kidney artery which is exercisable to stenting in the distance of <1cm of celiac artery, each of them is is in <4.5mm in diameter

18. Atypical anatomy of celiac artery in the form of separate exit of splenic and hepatic aortic artery

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Samodzielny Publiczny Szpital Kliniczny nr 2 PUM

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

An Independent Clinical Hospital 2 PUM

Szczecin, West Pomeranian Voivodeship, Poland

Site Status: RECRUITING

Countries

Poland

Central Contacts

Pawel Rynio

Role: CONTACT

p.rynio@spsk2.szczecin.pl

914661156

Facility Contacts

Pawel Rynio, MD PHD

Role: primary

p.rynio@spsk2-szczecin.pl

+914661156

Other Identifiers

2020/ABM/01/00121/P/02

Identifier Type: -

Identifier Source: org_study_id